Out-licensing: Biotechnology & Genetic disorders/Severe combined immunodeficiency

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Open Innovation for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Partneringtools; Reports; Partnering Consulting; Due Diligence; Comparison
Due Diligence: Overview; Top Applications; Online Panel Discussions; Request Consultation
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs; Forums
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing Ltd
is a division of

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..1 of 1 - per page
Order by

A method of providing a therapeutic effect in human patients by administering to the patient CD34+ cells obtained from umbilical cord blood. More

Displaying 1..1 of 1 - per page
Order by

Industry sector: Biotechnology del
Therapeutic target: Genetic disorders del; Severe combined immunodeficiency del

Industry sector: Assay systems; Diagnostic test systems; Gene therapy; Human diagnostics; Human therapeutics; Nanotechnology; Other; Research supplies; Stem cells
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Industry news: Pharmalicensing provides comprehensive industry coverage.